A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
Study Number: A222004
Study Summary:
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
Status: Open
Open at all clinics. Not actively screening – Contact Navigator
No use of androgens, progesterone analogs, or other appetite stimulants within the past month.
Study Coordinator(s)
- Navigator Courtney, 309-243-3660 cbrown@illinoiscancercare.com
- Kelsey, 309-243-3618 kfay@illinoiscancercare.com
- Erica, 309-243-3626 eraynor@illinoiscancercare.com
